Imaging in Tumor Immunology

다국어 초록 (Multilingual Abstract)

Recent advances in immune modulation have made impressive progress in cancer immunotherapy. Because dynamic nature of the immune response often makes it difficult to evaluate therapeutic outcomes, innovative imaging technologies have been developed to enable non-invasive visualization of immune cells and tumors in their microenvironment. This review summarizes the current tumor immunology and describes new innovative imaging methods with great potential to obtain non-invasive real-time insights into the complex functions of the immune system and into the management of cancer immunotherapy.

참고문헌 (Reference)

1 Obexer P, "X-linked inhibitor of apoptosis proteins : a critical resistance regulator and therapeutic target for personalized cancer therapy" 4 : 197-200, 2014

2 Chanmee T, "Tumor-associated macrophages as major players in the tumor microenvironment" 6 : 1670-1690, 2014

3 Muylle K, "Tumor targeting and radiation dose of radioimmunotherapy with Y-90 rituximab in CD20+ B cell lymphoma as predicted by Zr-89 rituximab immune-PET" 42 : 1304-1314, 2015

4 Lampreht Tratar U, "Transgenic mouse model in cancer research" 8 : 268-, 2018

5 Parente-Pireira AC, "Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice" 31 : 710-718, 2011

6 Dunn GP, "The three Es of cancer immunoediting" 22 : 329-360, 2004

7 Miller JF, "The journey from discoveries in fundamental immunology to cancer immunotherapy" 27 : 439-449, 2015

8 Pandolfi F, "The immune response to tumors as a tool toward immunotherapy" 2011 : 894704-, 2011

9 Mantovani A, "The growing diversity and spectrum of action of myeloid-derived suppressor cells" 40 : 3317-3320, 2010

10 Mojic M, "The dark side of IFN-γ : its role in promoting cancer immunoevasion" 19 : 89-94, 2017

11 Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy" 12 : 252-264, 2012

12 Vis R, "Tc-99m anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis" 47 : 1198-1207, 2016

13 Wang B, "Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice" 14 : R39-R43, 2012

14 Chen CL, "Targeted superparamagnetic iron oxide nanoparticles for in vivo MRI of T cells in rheumatoid arthritis" 19 : 233-244, 2017

15 Meidenbauer N, "Survival and tumor localization of adoptively transferred melan-A specific T cells in melanoma patients" 170 : 2161-2169, 2003

16 Wu S, "Stimulation of ovarian tumor cell proliferation with monocyte products including IL-1-α. IL-6 and TNF-α" 166 : 997-1007, 1992

17 Quezada SA, "Shifting the equilibrium in cancer immunoediting : from tumor tolerance to eradication" 241 : 104-118, 2011

18 Keu KV, "Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma" 9 : eaag2196-, 2017

19 Wolfs E, "Radiolabeling strategies for radionuclide imaging of stem cells" 11 : 254-274, 2015

20 Oude Munnink TH, "PET with Zr-89 labeled transforming growth factor-β antibody fresolimumab in tumor models" 52 : 2001-2008, 2011

21 Deri MA, "PET imaging with Zr-89 from radiochemistry to the clinic" 40 : 3-14, 2013

22 Perez-Medina C, "PET imaging of TAM with Zr-89 labeled highdensity lipoprotein nanoparticles" 56 : 1272-1277, 2015

23 Cella M, "Origin, maturation and antigen presenting function of dendritic cells" 9 : 10-16, 1997

24 Chen DS, "Oncology meets immunology : the cancer immunity cycle" 39 : 1-10, 2013

25 Disis ML, "Oncogenic proteins as tumor antigens" 8 : 637-642, 1996

26 Hartimath SV, "Noninvasive monitoring of cancer therapy induced activated T cells using F-18 FB-IL-2 PET imaging" 6 : e1248014-, 2017

27 Umansky V, "New insights into tumor-host interactions in lymphocyte metastasis" 74 : 353-363, 1996

28 Mittal D, "New insights into cancer immunoediting and its three phases" 27 : 16-25, 2014

29 Acharya N, "NRP1 cripples immunological memory" 21 : 972-973, 2020

30 Dimitrakopoulou-Strauss A, "Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT" 68 : 813-822, 2019

31 Meller B, "Monitoring of a new approach of immunotherapy with allogenic In-111 labeled NK cells in patients with renal cell carcinoma" 31 : 403-407, 2004

32 Dimitriadou V, "Mast cell-tumor interactions : for or against tumor growth and metastasis" 17 : 1541-1550, 1997

33 Zhou Y, "Mapping biological behaviors by application of lobger-lived positron emitting radionuclides" 65 : 1098-1111, 2013

34 Quaranta V, "Macrophages-mediated subversion of antitumor immunity" 8 : 747-752, 2019

35 Dong Z, "Macrophage-derived metallostase is responsible for the generation of angiostatin in Lewis lung cancer" 88 : 801-810, 1997

36 Kirsch IR, "Lymphocyte-specific genomic instability and risk of lymphoid malignancy" 9 : 207-215, 1997

37 Tirapu I, "Low surface expression of B7–1(CD80)is an immunoescape mechanism of colon carcinoma" 66 : 2442-2450, 2006

38 Dunn GP, "Interferons, immunity and cancer immunoediting" 6 : 836-848, 2006

39 Gibson HM, "Interferon γ PET imaging as a predictive tool for monitoring response to immunotherapy" 78 : 5706-5717, 2018

40 Pekarek LA, "Inhibition of tumor growth by elimination of granulocytes" 181 : 435-440, 1995

41 McCarthy CE, "In vivo imaging technologies to monitor the immune system" 11 : 1067-, 2020

42 Ottobrini L, "In vivo imaging of immune cell trafficking in cancer" 38 : 949-968, 2011

43 Pittet MJ, "In vivo imaging of T cell delivery to tumors after adoptive transfer therapy" 104 : 12457-12461, 2007

44 Galli F, "In vivo imaging of NK cell trafficking in tumors" 56 : 1575-1580, 2015

45 El Ansary M, "Immunotherapy by autologous dendritic cell vaccine in patients with advanced hepatocellular carcinoma" 139 : 39-48, 2013

46 Rook G, "Immunology" Mosby 131-138, 1998

47 Male D, "Immunology" Mosby 1-12, 1998

48 Owen M, "Immunology" Mosby 83-92, 1998

49 Monjazeb AR, "Immunoediting and antigen loss : overcoming the achilles heel of immunotherapy with antigen non-specific therapies" 3 : 197-, 2013

50 Li D, "Immuno-PET imaging of Zr-89 labeled anti-PD-L1 domain antibody" 15 : 1674-1681, 2018

51 Liu K, "Immune tolerance after delivery of dying cells to dendritic cells in situ" 196 : 1091-1097, 2002

52 Vinay DS, "Immune evasion in cancer: mechanistic basis and therapeutic strategies" 35 (35): S185-S198, 2015

53 Gaudet J, "Imaging cancer immunology : tracking immune cells in vivo with magnetic particle imaging" 202 (202): 1307-1315, 2019

54 Mansfield J, "Imaging cancer immunology : systemic tracking of immune cells in vivo with magnetic particle imaging" 61 (61): 101-106, 2020

55 Malviya G, "Imaging T lymphocytes in inflammatory diseases : a nuclear medicine approach" 58 : 237-257, 2014

56 Ramos CA, "Human papilloma-virus type 16 E6/E7-specific cytoxic T lymphocytes for adoptive immunotherapy of HPVassociated malignancies" 36 : 66-76, 2013

57 Yamauchi T, "Hippo pathway in mammalian adaptive immune system" 8 : 398-, 2019

58 Lin A, "Heterogeneity of HLA-G expression in cancers facing the challenges" 9 : 2164-2169, 2018

59 Zettlitz KA, "F-18 labeled anti-human CD20 cys-diabody for sameday immune PET in a model of aggressive B-cell lymphoma in human CD20 transgenic mice" 46 : 489-500, 2019

60 Malik S, "Epithelial ovarian cancer : a cytokine propelled disease" 64 : 617-622, 1991

61 Shah MN, "Early PET/CT as a predictor of response after CTL019 chimeric antigen receptor-T-cell therapy in B-cell non-Hodgkin’s lymphoma" 20 : 1415-1418, 2018

62 Natarajan A, "Dosimetry prediction for clinical translocation of Cu-64 pembrolizumab immune-PET targeting human PD-1 expression" 8 : 633-, 2018

63 Jackute J, "Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer" 19 : 3-, 2018

64 Kelly GL, "Different patterns of Epstein-Barr virus latency in endemic Burkitt’s lymphoma(BL)lead to distant variants within BL-associated gene expression signature" 87 : 2882-2894, 2013

65 Feldmann M, "Design of effective immunotherapy for human autoimmunity" 435 : 612-619, 2005

66 Banchereau J, "Dendritic cells and the control of immunity" 392 : 245-252, 1998

67 Cai L, "Defective HLA class I antigen processing machinery in cancer" 67 : 999-1009, 2018

68 Igney FH, "Death and anti-death : tumor resistance to apoptosis" 2 : 277-288, 2002

69 Syn NL, "De-novo and acquired resistance to immune checkpoint targeting" 18 : e731-41, 2017

70 Higashikawa K, "Cu-64 DOTA anti-CTLA-4 monoclonal antibody enabled PET visualization of CTLA-4 on the T cell infiltrating tumor tissue" 9 : e109866-, 2014

71 Chawla A, "Control of macrophage activation and function by PPARs" 106 : 1559-1569, 2010

72 Stanton SE, "Concurrent SPECT-PET/CT imaging as a method for tracking adoptively transferred T cells in vivo" 4 : 27-32, 2016

73 Kroemer G, "Classification of cell death : recommendations of the nomenclature committee of cell death" 12 (12): 1463-1467, 2005

74 Abbas AK, "Cellular and Molecular Immunology" Elsevier 409-416, 2018

75 Kim R, "Cancer immunoediting from immune surveillance to immune escape" 121 : 1-14, 2007

76 Obeid M, "Calreticulin exposure dictates the immugeneity of cancer cell death" 13 : 54-61, 2007

77 Buchbinder EI, "CTLA-4 and PD-1 pathways : similarities, differences and implications of their inhibition" 39 : 98-106, 2016

78 Brunner-Weinzierl MC, "CTLA-4 and PD-1 control of T cell motility and migration : implication for tumor immunotherapy" 9 : 2737-2742, 2018

79 Polanczyk MJ, "Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4 + CD25 + Foxp3 + and CD4 + CD25-Foxp3 + T cells" 17 : 219-224, 2019

80 Frenzel A, "Bcl2 family proteins in carcinogenesis and the treatment of cancer" 14 : 584-596, 2009

81 Wu AM, "Arming antibodies : prospects and challenges for immunoconjugates" 23 : 1137-1146, 2005

82 Wold ED, "Antibody therapeutics in oncology" 2 : 108-117, 2016

83 Feins S, "An introduction to chimeric antigen receptor(CAR)T cell immunotherapy for human cancer" 94 : S3-9, 2019

84 Tavare R, "An effective immune-PET imaging method to monitor CD8-dependent responses to immunotherapy" 76 : 73-82, 2016

85 Hsieh MY, "Alpha-fetpprotein in patients with hepatoma after transcatheter arterial embolization" 7 : 614-617, 1992

86 Bernhard H, "Adoptive transfer of autologous HER-2 specific, cytotoxic T lymphocytes for the treatment of HER-2 overexpressing breast cancer" 57 : 271-280, 2008

87 Shah W, "A reversed CD4/CD8 ratio of TIL and a high percentage of CD4+ FOXP3+regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix" 8 : 59-66, 2011

88 Chatterjee S, "A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors" 7 : 10215-10227, 2016

89 Lake RA, "A better way for a cancer cell to die" 354 : 2503-2504, 2006